Coronavirus Equities Blog

Vaccine Hopes Shouldn't Drive Healthcare Investing Strategies

24 November 2020

4 min read

Healthcare stocks are once again in focus as a result of promising news of COVID-19 vaccines. But investors shouldn’t hunt for the pandemic’s panacea. Focusing on business fundamentals is a much better way to find healthcare stocks with long-term potential than searching for the next big drug.

Investors have been captivated by strong trial results for COVID-19 vaccines from Pfizer and Moderna this month. As shares of both companies surged on the news, and two additional vaccine candidates reported encouraging trial results, investors might be tempted to look for blockbuster drugs for COVID-19 or other diseases when searching for healthcare stocks.

Yet the MSCI World Health Care Index has actually underperformed the broad global benchmark since Pfizer’s announcement on November 9 through November 20. And in fact, the recent successes reinforce why we think equity investors should focus on business rather than science to identify promising healthcare stocks.

Competition Could Erode Vaccine Profitability

For vaccine frontrunners, it’s still early days. More data is needed to validate the efficacy of the drugs, and vaccine safety is still under scrutiny. Historically, vaccine success rates are 33% from phase 1 trials to approval. While the current candidates look promising, about 70 companies worldwide are working on more than 200 novel coronavirus vaccines (Display). Most are still in very early development stages, and it’s still hard to predict which will make it to the finish line.

Competition for COVID-19 Vaccines Could Erode Profitability

Bar chart shows the number of COVID-19 vaccines in various stages of development worldwide.

For illustrative purposes only
As of November 20, 2020
Source: Milken Institute and AllianceBernstein (AB)

Given the huge amounts of money being invested, it’s likely that more than one coronavirus vaccine will make it to market. Demand will be massive, as every country on the planet seeks to procure enough doses for their populations. However, given the expected competition among several products, we don’t think COVID-19 vaccines will be very profitable products.

The race for a vaccine is understandably alluring. Everybody wants to be part of the drug that will save the world from the pandemic, just like everybody wants to invest in the cure for cancer, Alzheimer’s disease or countless other illnesses. But it’s notoriously difficult to predict successful drugs in development. The failure rate for drugs that enter human trials is about 90%. Among thousands of biotech companies founded since 1976, only 59 have more than one approved drug, while only five companies had more than four approved drugs, based on industry data through 2017 (Display).

Consistently Successful Drug Development Is Hard

Drug Development Since 1976

A step-shaped diagram illustrates that only a small number of biotech companies succeed at bringing approved drugs to market.

For illustrative purposes only
As of December 31, 2017
Source: EvaluatePharma, GlobalData, Morgan Stanley, Pharmaprojects and AllianceBernstein (AB)

To be sure, select companies that develop drugs may be good investments. But an investment thesis shouldn’t be based on the science behind a COVID vaccine or any other treatment, in our view.

What Defines a Solid Healthcare Business Model?

Identifying healthcare companies with strong business models is a much better strategy. We believe that this approach leads to a far more consistent and explainable path of performance and long-term returns.

Strong healthcare businesses have similar features to good businesses in other sectors. In particular, we think high or improving returns on capital and a strong reinvestment rate signal a business advantage. When a company generates profits above its costs of capital, and reinvests those profits back into the business, our research suggests that the underlying business model typically has staying power.

Medical Themes Worth Watching

Several healthcare themes underpin solid business dynamics for healthcare companies. Improvements in diagnostics are accelerating because of advances related to human genome sequencing. Minimally invasive therapies and robotics are helping hospitals increase patient turnover and saving costs for healthcare systems. Telemedicine has received a boost during the pandemic as more patients seek to consult with doctors virtually.

Companies in these areas can provide access to promising growth potential that’s easier to forecast than a hot drug prospect. For example, Illumina is a leading supplier of instruments and reagents to sequence DNA, which is used for clinical diagnostics in areas such as oncology, and has demonstrated advantages in accuracy and cost versus competitors. Edwards Lifesciences manufactures aortic valves that can help heart patients avoid open-heart surgery-a benefit for hospitals and patients in normal times, especially during a pandemic.

For Solid Businesses, Blockbuster Drugs Are a Bonus

Some attractive healthcare companies have faced a disruption to demand as COVID-19 led to a reprioritization of medical procedures for individuals and hospitals. However, in our view, products and services that create efficiencies for patients and healthcare systems will prevail over time, especially when conditions in the industry normalize in a post-COVID world. And the business benefits created by these companies can be identified and analyzed today.

When a COVID-19 vaccine comes to market, we will welcome its success as much as anyone, hoping for a return to normalcy. But equity investors shouldn’t be distracted by headlines and dramatic stock moves of vaccine winners. Healthcare portfolios should focus on companies with long-term business advantages, and if one happens to come up with a COVID-19 vaccine or another blockbuster drug, consider that a bonus for an otherwise solid position.

The views expressed herein do not constitute research, investment advice or trade recommendations and do not necessarily represent the views of all AB portfolio-management teams. Views are subject to revision over time.

About the Author

This information is for exclusive use of the wholesale person to whom it is provided and is not to be relied upon by any other person. It is not intended for retail or public use and may not be further distributed without prior written consent of ABAL.
This webpage has been prepared by AllianceBernstein Australia Limited (“ABAL”)—ABN 53 095 022 718, AFSL 230 698. Information in this webpage is only intended for persons that qualify as “wholesale clients,” as defined by the Financial Markets Conduct Act 2013’, and is not to be construed as advice. This webpage is provided solely for informational purposes and is not an offer to buy or sell securities. The information, forecasts and opinions set forth in this webpage have not been prepared for any recipient’s specific investment objectives, financial situation or particular needs. Neither this webpage nor the information contained in it are intended to take the place of professional advice.
You should not take action on specific issues based on the information contained in this webpage without first obtaining professional advice. Past performance does not guarantee future results. Projections, although based on current information, may not be realized. Information, forecasts and opinions can change without notice and ABAL does not guarantee the accuracy of the information at any particular time. Although care has been exercised in compiling the information contained in this webpage, ABAL does not warrant that this webpage is free from errors, inaccuracies or omissions. ABAL disclaims any liability for damage or loss arising from reliance upon any matter contained in this webpage except for statutory liability which cannot be excluded.
No reproduction of the materials on this webpage may be made without the express written permission of ABAL. This information is provided for persons in Australia only and is not being provided for the use of any person who is in any other country.